0001415889-24-022620.txt : 20240830 0001415889-24-022620.hdr.sgml : 20240830 20240830160443 ACCESSION NUMBER: 0001415889-24-022620 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240828 FILED AS OF DATE: 20240830 DATE AS OF CHANGE: 20240830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fordyce Marshall CENTRAL INDEX KEY: 0001859453 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40407 FILM NUMBER: 241269829 MAIL ADDRESS: STREET 1: C/O VERA THERAPEUTICS, INC. STREET 2: 8000 MARINA BOULEVARD, SUITE 120 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vera Therapeutics, Inc. CENTRAL INDEX KEY: 0001831828 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812744449 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD, SUITE 120 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 650-770-0077 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD, SUITE 120 CITY: BRISBANE STATE: CA ZIP: 94005 4 1 form4-08302024_080840.xml X0508 4 2024-08-28 0001831828 Vera Therapeutics, Inc. VERA 0001859453 Fordyce Marshall C/O VERA THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 120 BRISBANE CA 94005 true true false false PRESIDENT AND CEO 1 Class A Common Stock 2024-08-28 4 M 0 14925 2.8968 A 337592 D Class A Common Stock 2024-08-28 4 S 0 14925 36.8001 D 322667 D Class A Common Stock 2024-08-28 4 M 0 700 2.8968 A 323367 D Class A Common Stock 2024-08-28 4 S 0 700 37.5357 D 322667 D Class A Common Stock 2024-08-28 4 S 0 13995 36.8241 D 308672 D Class A Common Stock 2024-08-28 4 S 0 700 37.5286 D 307972 D Stock Option (Right to Buy) 2.8968 2024-08-28 4 M 0 15625 0 D 2030-12-15 Class A Common Stock 15625 842962 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.59, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.44, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.61, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. /s/ Joseph R. Young, Attorney-in-Fact 2024-08-30